Lilly Posts Higher Drug Sales, Plans to Increase DividendBy
Diverse pipeline will help revenue growth over next decade
Adjusted earnings of 86 cents a share match analyst estimates
Eli Lilly & Co. posted second-quarter earnings that matched analysts’ estimates as revenue surged, led by growing U.S. sales of the company’s top drugs such as the erectile dysfunction pill Cialis and the diabetes treatment Humalog.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.